Clinical Trial
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Cancer Type
Lung
Protocol Number
202601126
Principal Investigator
Cittolin Santos, Giordano
Learn more about this study at
clinicaltrials.gov
For more information contact us here:
Phone
800-600-3606Brief Summary
This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
Protocol Interventions
Drug: Durvalumab 50 MG/ML
Learn About Clinical Trials
Clinical trials are research studies that help us find new ways to prevent, diagnose, and treat cancer. If you are interested in participating in a clinical trial, our team will help you find a study that is right for you. Call us to speak with a Siteman care coordinator.